How the test-to-treat pillar of the U.S. Covid strategy is failing patients

The federal “test-to-treat” program, announced in March, is meant to reduce covid hospitalizations and deaths by quickly getting antiviral pills to people who test positive. But even as cases rise again, many Americans don’t have access to the program.
Pfizer’s Paxlovid and Merck’s…

Source: medcitynews.com – Read more